Cargando…

New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is an incurable, progressive neurodegenerative disorder. AD is a complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging, genetic factors, and epigenetic changes are the main risk factors for AD. Two aggregation-prone proteins play a decisi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Penke, Botond, Szűcs, Mária, Bogár, Ferenc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049476/ https://www.ncbi.nlm.nih.gov/pubmed/36982456 http://dx.doi.org/10.3390/ijms24065383

Ejemplares similares

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis
por: Penke, Botond, et al.
Publicado: (2020)

Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands
por: Bogár, Ferenc, et al.
Publicado: (2022)

β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
por: Penke, Botond, et al.
Publicado: (2017)

Heat Shock Proteins and Autophagy Pathways in Neuroprotection: From Molecular Bases to Pharmacological Interventions
por: Penke, Botond, et al.
Publicado: (2018)

Novel High Affinity Sigma-1 Receptor Ligands from Minimal Ensemble Docking-Based Virtual Screening
por: Dvorácskó, Szabolcs, et al.
Publicado: (2021)

The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
por: Penke, Botond, et al.
Publicado: (2018)

Effects of sub-chronic, in vivo administration of sigma-1 receptor ligands on platelet and aortic arachidonate cascade in streptozotocin-induced diabetic rats
por: Váczi, Sándor, et al.
Publicado: (2022)

Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article
por: Szucs, Botond, et al.
Publicado: (2019)

New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
por: Chen, Haishu, et al.
Publicado: (2023)

Examination of Longitudinal Alterations in Alzheimer’s Disease-Related Neurogenesis in an APP/PS1 Transgenic Mouse Model, and the Effects of P33, a Putative Neuroprotective Agent Thereon
por: Szögi, Titanilla, et al.
Publicado: (2022)

Studies for Improving a Rat Model of Alzheimer’s Disease: Icv Administration of Well-Characterized β-Amyloid 1-42 Oligomers Induce Dysfunction in Spatial Memory
por: Kasza, Ágnes, et al.
Publicado: (2017)

Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population
por: Gustavsson, Erik, et al.
Publicado: (2021)

Discovering Biomarkers and Pathways Shared by Alzheimer’s Disease and Ischemic Stroke to Identify Novel Therapeutic Targets
por: Rahman, Md. Rezanur, et al.
Publicado: (2019)

Molecular Aspects of a Diet as a New Pathway in the Prevention and Treatment of Alzheimer’s Disease
por: Doroszkiewicz, Julia, et al.
Publicado: (2023)

Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice: A Novel Mechanism Presenting the Protein Fe65 as a Target
por: Szögi, Titanilla, et al.
Publicado: (2019)

A Novel Method to Identify Differential Pathways in Hippocampus Alzheimer’s Disease
por: Liu, Chun-Han, et al.
Publicado: (2017)

Dihydropyridine Derivatives Modulate Heat Shock Responses and have a Neuroprotective Effect in a Transgenic Mouse Model of Alzheimer’s Disease
por: Kasza, Ágnes, et al.
Publicado: (2016)

Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
por: Cummings, Jeffrey L., et al.
Publicado: (2023)

The pathway to secondary prevention of Alzheimer's disease
por: McDade, Eric, et al.
Publicado: (2020)

Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
por: Dias, Kris Simone Tranches, et al.
Publicado: (2014)

Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
por: Fang, Jiansong, et al.
Publicado: (2022)

Novel tacrine–benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer’s Disease
por: Fancellu, Gaia, et al.
Publicado: (2019)

The Role of the JAK/STAT Signaling Pathway in the Pathogenesis of Alzheimer’s Disease: New Potential Treatment Target
por: Rusek, Marta, et al.
Publicado: (2023)

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
por: Fišar, Zdeněk
Publicado: (2022)

Simultaneous Changes of Spatial Memory and Spine Density after Intrahippocampal Administration of Fibrillar Aβ (1–42) to the Rat Brain
por: Borbély, Emőke, et al.
Publicado: (2014)

Abeta(1-42) Enhances Neuronal Excitability in the CA1 via NR2B Subunit-Containing NMDA Receptors
por: Varga, Edina, et al.
Publicado: (2014)

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease
por: Panza, Francesco, et al.
Publicado: (2016)

A brain proteomic signature of incipient Alzheimer’s disease in young APOE ε4 carriers identifies novel drug targets
por: Roberts, Jackson A., et al.
Publicado: (2021)

Calcium Dysregulation in Alzheimer’s Disease: A Target for New Drug Development
por: Wang, Yong, et al.
Publicado: (2017)

Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer’s Disease
por: Cacciatore, Ivana, et al.
Publicado: (2016)

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
por: Corbett, Anne, et al.
Publicado: (2013)

Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy
por: Mandel, Silvia A., et al.
Publicado: (2010)

Acute intracerebral treatment with amyloid-beta (1–42) alters the profile of neuronal oscillations that accompany LTP induction and results in impaired LTP in freely behaving rats
por: Kalweit, Alexander Nikolai, et al.
Publicado: (2015)

Exploiting machine learning models to identify novel Alzheimer’s disease biomarkers and potential targets
por: Alamro, Hind, et al.
Publicado: (2023)

Targeting NMDA receptor in Alzheimer’s disease: identifying novel inhibitors using computational approaches
por: Siddiqui, Arif Jamal, et al.
Publicado: (2023)

Interacting Models of Amyloid-β and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer’s Disease
por: Priya, Khadgawat, et al.
Publicado: (2021)

Tau Oligomers as Potential Targets for Alzheimer’s Diagnosis and Novel Drugs
por: Guzmán-Martinez, Leonardo, et al.
Publicado: (2013)

Herbal therapy: a new pathway for the treatment of Alzheimer's disease
por: Tian, Jinzhou, et al.
Publicado: (2010)

Intermediate Phenotypes Identify Divergent Pathways to Alzheimer's Disease
por: Shulman, Joshua M., et al.
Publicado: (2010)

Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients
por: Bayraktar, Abdulahad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9aukmmsvaf3a5947g48silec2s